Lupin

Lupin Limited is a transnational pharmaceutical company that focuses on the production and marketing of a diverse range of generic and branded formulations, as well as active pharmaceutical ingredients (APIs). The company is recognized for its significant presence in various therapeutic areas, including Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastrointestinal, and Anti-Infectives. Lupin holds a leading position in the global market for Anti-TB and Cephalosporins. Additionally, it is engaged in the development of specialty products with a robust pipeline in high-barrier markets, including Inhalation, Biosimilars, and Complex Injectables. The majority of Lupin’s sales are generated from the United States, highlighting its strong international footprint in the pharmaceutical sector.

Christoph Funke

CTO and President

Ramesh Swaminathan

Executive Director, Global CFO and Head Corporate Affairs

11 past transactions

Eli Lilly - Huminsulin Business

Acquisition in 2024
Eli Lilly - Huminsulin Business is a unit of Eli Lilly that provides healthcare services including diabetes, effectively reducing blood sugar levels in adults and children.

Medisol

Acquisition in 2023
Medisol is a French pharmaceutical firm situated in Lyon that specializes in generic injectable pharmaceuticals manufactured in France using chemicals and materials supplied in France and the European Union. The Medisol product line is offered to hospitals and retail pharmacies throughout France.

Southern Cross Pharma

Acquisition in 2021
Southern Cross Pharma is a privately owned pharmaceutical company that specializes in developing, registering, and distributing generic products in the Australian and New Zealand markets. The company focuses on providing prescription medications primarily to retail pharmacies while also marketing its own-brand products, SXP, directly to the hospital sector. By streamlining the supply process, Southern Cross Pharma enables its clients to efficiently meet consumer demand for pharmaceutical products.

Symbiomix Therapeutics

Acquisition in 2017
Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for serious women's health infections, particularly those that have been historically overlooked. Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in antibiotics for gynecologic infections. Its lead product, Solosec (secnidazole), is a next-generation 5-nitroimidazole antibiotic designed for the one-time oral treatment of bacterial vaginosis. This drug is characterized by its enhanced pharmacokinetic properties, allowing for effective and well-tolerated delivery in a single dose. Symbiomix Therapeutics operates as a subsidiary of Lupin Inc.

Temmler Werke

Acquisition in 2015
The Temmler Group, with its 7 production sites in Europe, is one of the largest providers of contract services in the pharmaceutical environment. Temmler has a wide experience in formulation development of finished solid, semi-solid and liquid dosage forms, in manufacture, packaging, blinding, distribution and return handling of clinical trial supplies, in the optimization of established manufacturing processes as well as in the contract manufacture of medicinal products with marketing authorization, supplemented by Quality Control and Analytical services. Temmler offers services from stand-alone processes according to customer specifications, to strategic services comprising the entire supply chain.

Novel Laboratories

Acquisition in 2015
Novel Laboratories, Inc. is a pharmaceutical company focused on the research, development, and manufacturing of both generic and branded products across various therapeutic classes and dosage forms. The company's extensive product portfolio includes immediate and modified release tablets, capsules, powders, and a range of liquid formulations such as solutions and suspensions. Additionally, Novel Laboratories produces topical products like gels, lotions, foams, ointments, and creams, along with respiratory products, vaginal and rectal suppositories, and otic solutions. The company also specializes in injectables, including lyophilized powders and solutions in vials and ampules, as well as large volume parenterals and ophthalmic solutions. Through its diverse offerings, Novel Laboratories aims to meet the evolving needs of the pharmaceutical market.

GAVIS Pharmaceuticals

Acquisition in 2015
GAVIS Pharmaceuticals, LLC is a pharmaceutical manufacturer based in Franklin Township, New Jersey, specializing in the sales and distribution of niche drug products. The company offers a diverse range of pharmaceutical formulations, including analgesics, gastric anti-inflammatories, antidepressants, and antifungal medications. GAVIS focuses on providing effective healthcare solutions through its targeted product offerings in the pharmaceutical market.

JSC Biocom

Acquisition in 2015
JSC Biocom is a pharmaceutical company based in Stavropol, Russian Federation, founded in 1991. The company specializes in the production of generic pharmaceutical products, primarily in tablet and capsule forms. Its portfolio includes medications that target various systems of the body, such as the hemopoietic and cardiovascular systems, the alimentary system, the nervous system, and the musculoskeletal system. Additionally, JSC Biocom produces dermatological and antimicrobial agents. The company also provides contract manufacturing services for pharmaceuticals, catering to the needs of other businesses within the industry.

Medquímica Indústria Farmacêutica

Acquisition in 2015
Medquímica Indústria Farmacêutica S.A. is a pharmaceutical company based in Juiz de Fora, Brazil, established in 1975. It specializes in the development of solid and liquid medications, including over-the-counter drugs, generics, and dietary supplements. The company offers a diverse portfolio that encompasses products for various therapeutic areas such as cardiology and gastroenterology, as well as herbal remedies. Medquímica serves its customers through representatives throughout Brazil, ensuring a broad reach in the healthcare market. As of 2015, it operates as a subsidiary of Lupin Limited.

Pharma Dynamics

Acquisition in 2015
Pharma Dynamics (Pty) Ltd. is a pharmaceutical company based in Cape Town, South Africa, founded in 2001. The company specializes in providing a wide range of generic pharmaceuticals and offers products across various therapeutic categories, including cardiovascular, central nervous system, and pediatric care. Additionally, Pharma Dynamics supplies over-the-counter medications for conditions such as cold and flu, allergies, heartburn, and immune support. The company also focuses on critical hospital products, which include antibiotics and specialty healthcare solutions for both male and female patients. Pharma Dynamics primarily serves the South African market and operates as a subsidiary of Lupin Limited.

Laboratorios Grin

Acquisition in 2014
Laboratorios Grin is a pharmaceutical company that manufactures ophthalmological products, antivertiginosis, and oral antibiotics products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.